Immatics (IMTX) Short-Term Debt repayments (2022 - 2025)
Immatics recorded quarterly Short-Term Debt repayments of -$870704.5 in Q4 2025, down 0.92% quarter-over-quarter from -$862762.7 in Q3 2025, and down 3.93% year-over-year from -$906324.2 in Q4 2024.
Immatics' Short-Term Debt repayments history runs 4 years deep, the most recent figure standing at -$870704.5 for Q4 2025.
- In Q4 2025, Short-Term Debt repayments fell 3.93% year-over-year to -$870704.5; the TTM figure through Dec 2025 stood at -$3.5 million (down 1549.35% YoY), while the FY2025 annual figure was -$3.3 million, down 55.49% from the prior year.
- Short-Term Debt repayments came in at -$870704.5 for Q4 2025 at Immatics, down from -$862762.7 in the prior quarter.
- In the past five years, Short-Term Debt repayments ranged from a high of $3.1 million in Q4 2023 to a low of -$1.1 million in Q3 2023.
- A 4-year average of -$542186.7 and a median of -$850270.7 in 2024 frame the typical range for Short-Term Debt repayments.
- Across the five-year window, Short-Term Debt repayments soared 544.93% in 2023 and slumped 127.1% in 2024, its largest moves.
- Immatics' Short-Term Debt repayments stood at -$694788.5 in 2022, then soared by 544.93% to $3.1 million in 2023, then slumped by 127.1% to -$837778.8 in 2024, then retreated by 3.93% to -$870704.5 in 2025.
- According to Business Quant data, Short-Term Debt repayments over the past three periods registered -$870704.5, -$862762.7, and -$837778.8 for Q4 2025, Q3 2025, and Q4 2024 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Short-Term Debt repayments (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | 102,000.00 |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | - |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | - |
| 10 | Immatics | 1.80 Bn | 1.80 Bn | - | -870,704.55 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -870,704.55 |
| Dec 31, 2025 | -870,704.55 |
| Sep 30, 2025 | -862,762.66 |
| Sep 30, 2025 | -862,762.66 |
| Dec 31, 2024 | -837,778.79 |
| Dec 31, 2024 | -837,778.79 |
| Sep 30, 2024 | -912,620.41 |
| Sep 30, 2024 | -912,620.41 |
| Dec 31, 2023 | 3.09 Mn |
| Dec 31, 2023 | 3.09 Mn |
| Sep 30, 2023 | -1.10 Mn |
| Sep 30, 2023 | -1.10 Mn |
| Jun 30, 2023 | -1.09 Mn |
| Jun 30, 2023 | -1.09 Mn |
| Mar 31, 2023 | -929,514.02 |
| Mar 31, 2023 | -929,514.02 |
| Dec 31, 2022 | -694,788.46 |
| Dec 31, 2022 | -694,788.46 |
| Sep 30, 2022 | -774,354.69 |
| Sep 30, 2022 | -774,354.69 |
| Jun 30, 2022 | -752,274.97 |
| Jun 30, 2022 | -752,274.97 |
| Mar 31, 2022 | -773,290.69 |
| Mar 31, 2022 | -773,290.69 |